Age: 30.0
Sex: M
Vaccine: COVID19-2, UNK
Symptoms: Condition aggravated, Dry skin, Rash, Therapeutic response shortened
Clinical narrative: flare up; Dry elbows and Rash in groin area, scalp, elbows, and arm pit two weeks to a month before next SKYRIZI injection; Dry elbows and Rash in groin area, scalp, elbows, and arm pit  two weeks to a month before next Skyrizi injection; Dry elbows and Rash in groin area, scalp, elbows, and arm pit after receiving Covid-19 vaccine Moderna brand; This spontaneous case was reported by a consumer and describes the occurrence of CONDITION AGGRAVATED (flare up), DRY SKIN (Dry elbows and Rash in groin area, scalp, elbows, and arm pit two weeks to a month before next SKYRIZI injection), THERAPEUTIC RESPONSE SHORTENED (Dry elbows and Rash in groin area, scalp, elbows, and arm pit  two weeks to a month before next Skyrizi injection) and RASH (Dry elbows and Rash in groin area, scalp, elbows, and arm pit after receiving Covid-19 vaccine Moderna brand) in a 31-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 vaccination.    Co-suspect product included non-company product RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) solution for injection for Plaque psoriasis and Psoriatic arthritis.    Concurrent medical conditions included Plaque psoriasis (Moderate to Severe Chronic Plaque Psoriasis) and Psoriatic arthritis.   On 18-Mar-2022, the patient started RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) (Subcutaneous) Single-Dose Prefilled Syringe with Needle Guard. On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced CONDITION AGGRAVATED (flare up), DRY SKIN (Dry elbows and Rash in groin area, scalp, elbows, and arm pit two weeks to a month before next SKYRIZI injection), THERAPEUTIC RESPONSE SHORTENED (Dry elbows and Rash in groin area, scalp, elbows, and arm pit  two weeks to a month before next Skyrizi injection) and RASH (Dry elbows and Rash in groin area, scalp, elbows, and arm pit after receiving Covid-19 vaccine Moderna brand). At the time of the report, CONDITION AGGRAVATED (flare up) and RASH (Dry elbows and Rash in groin area, scalp, elbows, and arm pit after receiving Covid-19 vaccine Moderna brand) had not resolved and DRY SKIN (Dry elbows and Rash in groin area, scalp, elbows, and arm pit two weeks to a month before next SKYRIZI injection) and THERAPEUTIC RESPONSE SHORTENED (Dry elbows and Rash in groin area, scalp, elbows, and arm pit  two weeks to a month before next Skyrizi injection) outcome was unknown.            No concomitant medications were reported.  The patient had rash in groin area, scalp, elbows, and arm pit after receiving Covid-19 vaccine Moderna brand. The patient experienced flare up and had dry elbows and rash at groin area two weeks to a month before next Skyrizi injection.  The reporter causality for condition aggravated with respect to skyrizi injection was reported as probable. The reporter causality for localized rash with respect to skyrizi injection was reported as not related. No treatment medication was provided. Company comment: This spontaneous case concerns a 31-years-old male patient with Concurrent medical conditions included Plaque psoriasis (Moderate to Severe Chronic Plaque Psoriasis) and Psoriatic arthritis, treated with RISANKIZUMAB, who experienced the unexpected non- serious events of Condition aggravated, Dry skin and Therapeutic response shortened and Rash that occurred on unspecified day after a dose of mRNA-1273 bivalent BA.4-5 vaccine. Vaccination dose number and vaccination schedule was not disclosed. It was reported that the patient had rash in groin area, scalp, elbows, and arm pit after receiving Covid-19 vaccine Moderna brand. The patient experienced flare up and had dry elbows and rash at groin area two weeks to a month before next Skyrizi injection. No further information on risk factors, clinical course, relevant medical history, diagnostic investigations, concomitant medication, and treatment received were available for review. The outcome of events was reported as unknown. Patient's mentioned medical history remains confounder for the condition aggravated. The benefit-risk relationship of mRNA-1273 bivalent BA.4-5 vaccine is not affected by this report.